Search

Displaying results 4111 - 4120 of 10000 in total
  1. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.

  2. Drug

    Ferrous glycine sulfate

    go.drugbank.com/drugs/DB14501
    Approved

    Synonyms: Iron(II) glycine sulfate, Ferrous (II) Glycine Sulphate Complex
  3. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. … IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome

  4. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    It is being developed by EPIX Pharmaceuticals, Inc. … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.

  5. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

  6. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Categories: Topoisomerase II InhibitorsSynonyms: 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
  7. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

  8. Drug

    Carbendazim

    go.drugbank.com/drugs/DB13009
    Investigational

    Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  10. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion